Please wait...


Generic Name: elosulfase alfa (EE loe SUL face AL fa)
Brand Names: Vimizim
Vimizim (elosulfase alfa) is used to treat Mucopolysaccharidosis Type IVA. Includes Vimizim side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Vimizim

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Vimizim (elosulfase alfa) is used to treat some of the symptoms of a genetic condition called mucopolysaccharidosis IV (4) type A, or MPS IV A, also called Morquio A syndrome. Elosulfase alfa contains an enzyme that occurs naturally in the body in healthy people. Some people lack this enzyme because of a genetic disorder. Elosulfase alfa helps replace this missing enzyme in such people. MPS IVA is a metabolic disorder in which the body lacks the enzyme needed to break down certain sugars and proteins. These substances can build up in the body, causing enlarged organs, abnormal bone structure, changes in facial features, breathing problems, heart problems, vision or hearing loss, and changes in mental or physical abilities. Learn more

Vimizim Side Effects

Vimizim Side Effects

Note: This document contains side effect information about elosulfase alfa. Some of the dosage forms listed on this page may not apply to the brand name Vimizim.

In Summary

Common side effects of Vimizim include: anaphylaxis, abdominal pain, fever, hypersensitivity reaction, nausea, and vomiting. Other side effects include: cyanosis, chest discomfort, constriction of the pharynx, cough, dyspnea, gastrointestinal signs and symptoms, hypotension, retching, skin rash, urticaria, erythema of skin, and flushing. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to elosulfase alfa: intravenous solution


Intravenous route (Solution)

Life-threatening anaphylactic reactions have occurred in some patients during elosulfase alfa infusions. Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during elosulfase alfa infusions. Closely observe patients during and after elosulfase alfa administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and instruct them seek immediate medical care should symptoms occur. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.

Along with its needed effects, elosulfase alfa (the active ingredient contained in Vimizim) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking elosulfase alfa:

More common

  • Chills
  • cough
  • difficulty with swallowing
  • dizziness
  • fast heartbeat
  • fever
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • skin rash, hives, or itching
  • tightness in the chest
  • unusual tiredness or weakness

Some side effects of elosulfase alfa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Abdominal or stomach pain
  • headache
  • vomiting

For Healthcare Professionals

Applies to elosulfase alfa: intravenous solution


The more commonly reported adverse reactions include pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue.


Very common (10% or more): Hypersensitivity reactions (including anaphylaxis; 18.7%)

Common (1% to 10%): Anaphylaxis

During clinical trials, 7.5% of patients (n=18/235) experienced signs and symptoms of anaphylaxis. These 18 patients experienced 26 anaphylactic reactions. These cases occurred 30 to 180 minutes after the start of the infusion. Anaphylaxis occurred as late into treatment as the 47th infusion. Hypersensitivity reactions (including anaphylaxis) occurred in 18.7% (n=44/235) of patients.


In clinical trials, 96% of patients experienced infusion reactions (IRs). IRs may include allergic reactions. Thirty-five patients (15.2%) discontinued at least one infusion due to an IR. Sixty (0.66%) of the 9,126 infusions administered in the clinical trials were discontinued due to an IR. 17.3% of patients had an infusion reaction requiring medical intervention. In 13 out of 231 patients and less than 1% of the total infusions, the infusion was discontinued, and medical intervention was required.

Very Common (10% or more): Infusion reaction (up to 96%)


All patients tested positive at least once during the trial for neutralizing antibodies capable of inhibiting the drug from binding to the mannose-6-phosphate receptor; this receptor binding is needed for drug intake into cells.

Very common (10% or more): Development of anti-drug antibodies (100%), tested positive for neutralizing antibodies (100%)


Very common (10% or more): Pyrexia (33%), chills (10.3%), fatigue (10.3%)


Very common (10% or more): Vomiting (31%), nausea (24%), abdominal pain (21%)

Nervous system

Very common (10% or more): Headache (26%)

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Vimizim